TP53 and neoplasm: In vivo experiments showed that AMG-232 (10, 25, 75 mg kg−1, orally, once a day) activated the p53 pathway, effectively inhibited the growth of xenogeneic tumors in mice, blocked viral DNA synthesis, induced apoptosis, and caused dose-dependent tumor growth inhibition (ED50 = 16 mg kg−1).385–387 The phase I clinical trial of AMG-232 (NCT01723020) began in November 2012.